Phathom Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Phathom Pharmaceuticals details a year of leadership transition and significant commercial momentum for VOQUEZNA in its 2026 proxy statement.
NASDAQ
DEFA14A: Phathom Pharmaceuticals Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
Phathom Pharmaceuticals has scheduled its annual stockholder meeting for June 3, 2025, and is seeking votes on director elections, auditor ratification, executive compensation, and the frequency of say-on-pay votes.
NASDAQ
Phathom Pharmaceuticals announces its 2025 annual meeting of stockholders to be held virtually on June 3, 2025, outlining proposals for director elections, auditor ratification, executive compensation, and voting frequency.
NASDAQ
Phathom Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on May 23, 2024, with voting open until May 22, 2024.
NASDAQ
Phathom Pharmaceuticals will hold its annual stockholder meeting virtually on May 23, 2024, to elect directors and ratify the appointment of its independent accounting firm.